Editing Propylhexedrine (section)

=== Brand names ===

==== Benzedrex inhaler ====
[[File:Benzedrex.jpg|thumb|Benzedrex inhaler, {{circa|2023}}, manufactured by B. F. Ascher & Co.]]
Propylhexedrine, as a nasal decongestant, is currently marketed under the brand name Benzedrex. The name Benzedrex was initially trademarked by [[Smith, Kline & French]] in 1944.<ref>{{Cite web |title=Benzedrex Trademark of B.F. Ascher & Company Inc - Registration Number 0896775 - Serial Number 72340742 |url= http://trademarks.justia.com/723/40/benzedrex-72340742.html |url-status=dead |archive-url= https://archive.today/20230716051433/https://trademarks.justia.com/723/40/benzedrex-72340742.html |archive-date=July 16, 2023 |access-date=2023-07-16 |website=Justia |language=en}}</ref> The brand was passed onto Menley James Laboratories (through a subsidiary, NuMark Laboratories) in 1990, and was finally acquired by B. F. Ascher & Co. in 1998.<ref>{{Cite web | vauthors = Robertson V |date=February 17, 2004 |title=Prince v. B.F. Ascher Company, Inc., 90 P.3d 1020 (Okla. Civ. App. 2004) |url=https://casetext.com/case/prince-v-bf-ascher-company-inc |url-status=live |archive-url=https://ghostarchive.org/archive/20230716060731/https://casetext.com/case/prince-v-bf-ascher-company-inc |archive-date=16 July 2023 |access-date=2023-07-16 |website=CaseText }}</ref><ref>{{Cite web |date=March 1, 1999 |title=B.F. Ascher marks 50th year. |url= https://www.thefreelibrary.com/B.F.+Ascher+marks+50th+year.-a054082926 |archive-url= https://archive.today/20230809072522/https://www.thefreelibrary.com/B.F.+Ascher+marks+50th+year.-a054082926 |archive-date=August 9, 2023 |access-date=2023-08-09 |website=The Free Library |publisher=Chain Drug Review}}</ref>

==== Dristan inhaler ====
[[File:Dristan_Inhaler.jpg|thumb|upright|Dristan-brand inhaler, {{circa|1966}} manufactured by [[Whitehall Laboratories]] ]]
Propylhexedrine was also sold in inhaler form by [[Whitehall Laboratories]] (Wyeth) under the [[Dristan]] brand name as an inhaler.<ref>{{Cite web |date=November 24, 1989 |title=Action in Respect of International Conventions on Narcotic Drugs and Psychotropic Substances |url=https://iris.who.int/bitstream/handle/10665/163484/EB85_23_eng.pdf?sequence=1 |archive-url=https://web.archive.org/web/20231029070234/https://iris.who.int/bitstream/handle/10665/163484/EB85_23_eng.pdf?sequence=1 |archive-date=October 29, 2023 |access-date=October 29, 2023 |website=[[World Health Organization]] }}</ref> In January 1966, propylhexedrine replaced [[mephentermine]] as the active ingredient in the product.<ref>{{cite journal | vauthors = Angrist BM, Schweitzer JW, Gershon S, Friedhoff AJ | title = Mephentermine psychosis: misuse of the Wyamine inhaler | journal = The American Journal of Psychiatry | volume = 126 | issue = 9 | pages = 1315–1317 | date = March 1970 | pmid = 5413209 | doi = 10.1176/ajp.126.9.1315 }}</ref> The Dristan inhaler has since been discontinued. Furthermore, Wyeth was acquired by [[Pfizer]] in 2009. All products currently sold under the [[Dristan]] brand are manufactured by Foundation Consumer Brands; Foundation Consumer Brands acquired the Dristan brand in 2020.<ref>{{Cite web |date=October 1, 2020 |title=Foundation Consumer Healthcare to Add Seven Over-the-Counter Brands to Expanding Portfolio of Healthcare Products |url=https://foundationch.com/assets/press-release/2020-10-01.pdf |archive-url=https://web.archive.org/web/20231113224757/https://foundationch.com/assets/press-release/2020-10-01.pdf |archive-date=November 13, 2023 |access-date=November 13, 2023 |website=Foundation Consumer Brands |publisher=[[Kelso & Company]]}}</ref> Foundation Consumer Brands is itself owned by [[Kelso & Company]].

==== Obesin ====
[[File:Obesin.jpg|thumb|left|Obesin pill-case, {{circa|1974}} manufactured by Fahlberg-List]]
Propylhexedrine has also seen use in [[Europe]] as an [[appetite suppressant]], under the brand name Obesin.<ref name="pmid2874970">{{cite journal | vauthors = Wesson DR | title = Propylhexdrine | journal = Drug and Alcohol Dependence | volume = 17 | issue = 2–3 | pages = 273–278 | date = June 1986 | pmid = 2874970 | doi = 10.1016/0376-8716(86)90013-X }}</ref> Obesin has been referenced in literature dating back to the 1950s.<ref name="Polster_1965">{{cite journal | vauthors = Polster H | title = Über eine Vergiftung mit dem Appetitzügler Propylhexedrin "Obesin", bei einem 3 Ährigen Kinde | trans-title = About poisoning with the appetite suppressant propylhexedrine "Obesin" in a 3-year-old child | language = de | journal = Archiv für Toxikologie | volume = 20 | pages = 271–273 | date = February 1965 | issue = 5 | pmid = 14272412 | doi = 10.1007/BF00577551 | s2cid = 19812917 }}</ref><ref name="Rose_1959" /> Obesin was manufactured by Fahlberg-List in [[East Germany]] from 1958 to around 1976. The discontinuation of Obesin was the result of increased regulatory restrictions on [[Over-the-counter drug|over-the-counter]] [[anorectic]]s. These restrictions began to be imposed in 1974.<ref name="Winter_1976">{{Cite journal | vauthors = Winter E |date=1976 |title=Bemerkungen zu Drogenmißbrauch und -abhängigkeit vom Amphetamin- Typ unter besonderer Berücksichtigung des Amphetaminils (Aponeuron (R) ) |trans-title=Comments on amphetamine-type drug abuse and dependence with special reference to amphetaminil (Aponeuron) |url=https://www.jstor.org/stable/45253962 |journal=Psychiatrie, Neurologie und medizinische Psychologie |language=DE |volume=28 |issue=9 |pages=513–525 |jstor=45253962 |issn=0033-2739}}</ref> Fahlberg-List itself dissolved in 1995.

==== Maliasin ====
[[File:Maliasin.jpg|thumb|left|Maliasin ([[Barbexaclone]]) carton, {{circa|2002}} manufactured by [[Knoll Pharmaceuticals]]]]

Propylhexedrine (in the form of levopropylhexedrine) is a component in the [[anticonvulsant]] preparation [[barbexaclone]]. It is included for the purpose of offsetting the [[barbiturate]]-induced [[sedation]] from [[phenobarbital]].<ref name="pmid2874970" /> Barbexaclone has been known under the brand name of Maliasin, manufactured by [[Abbott Laboratories]], as early as 1965.<ref>{{cite journal | vauthors = Krueger HJ, Schwarz H | title = [Clinical Communication on the Therapy of Epilepsy With Maliasin] | journal = Die Medizinische Welt | volume = 14 | pages = 690–692 | date = April 1965 | pmid = 14276849 }}</ref><ref>{{Cite web |title=MALIASIN Trademark - Registration Number 0797076 - Serial Number 72213021 |url=http://trademarks.justia.com/722/13/maliasin-72213021.html |url-status=dead |archive-url=https://web.archive.org/web/20230716060838/https://trademarks.justia.com/722/13/maliasin-72213021.html |archive-date=16 July 2023 |access-date=2023-07-16 |website=Justia |language=en }}</ref> Maliasin has also been manufactured by [[Knoll Pharmaceuticals]]; Knoll is a company acquired by [[Abbott Laboratories]]. In 2010, Abbott discontinued sale of its barbexaclone preparation in many countries.<ref>{{Cite web | vauthors = Serracchiani D |date=January 31, 2011 |title=Parliamentary question {{!}} Maliasin {{!}} P-001035/2011 {{!}} European Parliament |url=https://www.europarl.europa.eu/doceo/document/P-7-2011-001035_EN.html |url-status=dead |archive-url=https://ghostarchive.org/archive/20230716050714/https://www.europarl.europa.eu/doceo/document/P-7-2011-001035_EN.html |archive-date=16 July 2023 |access-date=2023-07-16 |website=[[European Parliament]] |language=en }}</ref>

==== Eventin ====
Levopropylhexedrine has been used as an [[anorectic|appetite suppressant]] under the brand name Eventin. Eventin's use has been documented as early as 1958.<ref>{{cite journal | vauthors = Hofer R, Locker A | title = [Therapeutic experiences with the appetite depressant eventin] | journal = Wiener Medizinische Wochenschrift | volume = 108 | issue = 14 | pages = 304–306 | date = April 1958 | pmid = 13558159 | url = https://pubmed.ncbi.nlm.nih.gov/13558159/ }}</ref>